CN106580933A - Application of 3,5-dihydroxy-2-[3,7-dimethyl-2(E),6-octadienyl]-bibenzyl - Google Patents
Application of 3,5-dihydroxy-2-[3,7-dimethyl-2(E),6-octadienyl]-bibenzyl Download PDFInfo
- Publication number
- CN106580933A CN106580933A CN201611092879.2A CN201611092879A CN106580933A CN 106580933 A CN106580933 A CN 106580933A CN 201611092879 A CN201611092879 A CN 201611092879A CN 106580933 A CN106580933 A CN 106580933A
- Authority
- CN
- China
- Prior art keywords
- dihydroxy
- dimethyl
- bibenzyl
- ptp1b
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 claims abstract 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000013641 positive control Substances 0.000 abstract description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 abstract 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 abstract 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 abstract 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229940100243 oleanolic acid Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 17
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 241000628997 Flos Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 241000109903 Aechmea abbreviata Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to application of a chemical compound 3,5-dihydroxy-2-[3,7-dimethyl-2(E),6-octadienyl]-bibenzyl. Activity screening tests prove: the chemical compound has the remarkable inhibitory activity for protein tyrosin phosphatase1B(PTP1B), and the activity thereof is stronger than that of a positive control drug oleanolic acid, so that the chemical compound can be prepared to form a pharmaceutical preparation as a PTP1B inhibitor used for treating diabetes, obesity and complications thereof, and also can be used for manufacturing health-care food beneficial to diabetics or obese patients.
Description
Technical field
The present invention relates to one kind extract from Chinese dark green Flos Aglaiae Odoratae blade separation 3,5- dihydroxy -2- [3,7- dimethyl -
2 (trans), 6- octadienyls]-bibenzyl and preparation method thereof.The invention further relates to the compound can be used to prepare PTP1B suppression
Agent, it can also be used to prepare the medicine or health food for the treatment of diabetes, obesity and its complication.
Background technology
Diabetes (diabetes mellitus) be one group caused by h and E factor interaction it is clinical comprehensive
Close disease.At present, diabetes are divided into into two classes, I- patients with type Ⅰ DM (insulin dependent diabetes mellitus (IDDM), insulin- typically
Dependent diabetes mellitus, IDDM) and II- patients with type Ⅰ DM (non-insulin-dependent diabetes mellitus, non-
Insulin-dependent diabetes mellitus, NIDDM).In diabetes, more than 90% is II- patients with type Ⅰ DM.
The characteristics of II- patients with type Ⅰ DM is that insulin sensitive tissues such as skeletal muscle, liver, fatty tissue are supported to insulin action
It is anti-.Protein-tyrosine-phosphatase (PTPases) associated protein tyrosine phosphatase in insulin action path in statocyte
Effect in change level is increasingly taken seriously, and becomes the new way for the treatment of II- patients with type Ⅰ DM.PTPase includes big nation's cross-film
(receptor type) and intracellular (non-receptor type) enzyme, participates in a series of important life processes of regulation and control.At present, it is logical in insulin to PTPase
In road, receptor or receptor metasomite affect the research of Normal insulin effect, be concentrated mainly on LAR-PTPase, SHPTP-2,
PTP1B。
PTP1B is first certified protein-tyrosine-phosphatase (protein tyrosine
Phosphatase), the experiment on mice rejected by PTP1B shows that PTP1B is acylated by the dephosphorization to Insulin receptor INSR, and then
Very important effect is played in insulin sensitivity and fat metabolic process is adjusted.Thus, it is selective, highly active
PTP1B inhibitor has important value in the treatment of II- patients with type Ⅰ DM, obesity and its complication.
The content of the invention
The present invention relates to a kind of compound 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl
And its production and use.The compound is that extraction, concentrating under reduced pressure, extraction, silica gel column chromatography are adopted from dark green Flos Aglaiae Odoratae
[3,7- dimethyl -2 are (anti-for method, gel column chromatography and 3,5- dihydroxy -2- obtained from high-efficient liquid phase color liquid method purification
Formula), 6- octadienyls]-bibenzyl { 3,5-dihydroxy-2- [3,7-dimethyl-2 (E), 6-octadienyl]
Bibenzyl }, its structure is determined by physicochemical constant measure and spectral data analysis.Jing preliminary Activity Screening Test card
It is bright：Compound for protein TYR esterase 1B (PTP1B) is with remarkable inhibiting activity, therefore can be used to prepare PTP1B suppression
Agent, it can also be used to prepare the medicine for the treatment of diabetes, obesity and its complication.
It is an object of the invention to provide compound 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls] -
The purposes of bibenzyl.Specifically, compound for protein tyrosine-phosphatase 1B (PTP1B) is with significant inhibitory action,
Can be used to prepare the medicine for the treatment of diabetes, obesity and its complication.
The present invention provides one kind and extraction, concentrating under reduced pressure, extraction, silica gel column chromatography, gel is adopted from dark green Flos Aglaiae Odoratae
Column chromatography and high-efficient liquid phase color liquid method prepare compound 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienes
Base]-bibenzyl method, comprise the following steps that：
1) prepare extract extractum
By dark green Flos Aglaiae Odoratae (A.abbreviata) the blade ethanol routinely seepage pressure effects crushed, extracting solution is obtained, will
Extracting solution concentrating under reduced pressure reclaims ethanol, obtains crude extract；
2) isolate and purify
(1) said extracted thing is dispersed in water into into suspension, suspension is used petroleum ether, ethyl acetate and positive fourth successively
Alcohol is extracted, and the concentration of gained extract respectively obtains Petroleum ether extraction extractum, ethyl acetate and extracts extractum and n-butanol extraction extractum；
(2) ethyl acetate extract is carried out into silica gel column chromatography, with petroleum ether/acetone gradient elution, is merged according to TLC colour developings
Similar stream part obtains 4 components A, B, C, D；Wherein component B is petroleum ether/acetone volume ratio 8:2 and 7:3 elution fraction Jing
Sephadex LH-20 gel filtration chromatographies【Chromatographic column specification：4.0 (diameter) cm × 120 (length) cm；Sephadex LH-20 coagulate
Glue dry weight：150g】, with methylene chloride/methanol volume ratio 1:1 eluting；Component B3, i.e. methylene chloride/methanol volume ratio 1:1 eluting
Volume is 90～120mL elution fractions, then Jing silica gel column chromatographies, with petroleum ether/acetone volume ratio 75:25 eluting, most after Jing systems
Standby type HPLC, with methanol/water 80:20 volume ratio eluting, obtain compound 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans),
6- octadienyls]-bibenzyl, entitled 3, the 5-dihydroxy-2- [3,7-dimethyl-2 (E), 6-octadienyl] of chemistry-
Bibenzyl, chemical structural formula is：
In above-mentioned preparation method, in extract extractum step is prepared, the ethanol for adopting that extracts is for 95% ethanol.
In above-mentioned preparation method, in separating step, the concentration of petroleum ether/acetone gradient elution is followed successively by volume ratio
100:0、90:10、80:20、70:30、50:50、30:70 and 0:100.
In above-mentioned preparation method, in separating step, the filler of the chromatographic column of the preparation HPLC is RP-18.
The invention provides prepared by 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyls
PTP1B inhibitor, diabetes medicament, the purposes of obesity drug.And protect for diabeticss or obese patient preparing
The application of health food.
The present invention tests 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl to PTP1B
Inhibitory activity.It is experimentally confirmed that 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl is to PTP1B
With obvious inhibitory action.
Therefore, 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl of the invention can be used to
PTP1B inhibitor medicaments are prepared, and then for preparing the medicine for the treatment of diabetes, obesity and its complication.
Description of the drawings
Fig. 1 PTP1B inhibitory activity test philosophies
Specific embodiment
Embodiment 13, the preparation of 5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl
(1) will be Chinese dark green Flos Aglaiae Odoratae (A.abbreviata) blade (the picking up from In Xishuangbanna of Yunnan) 7.8kg for crushing (dry
Weight) respectively with 95% ethanol percolate extraction of 40L three times, each percolation 2 days, united extraction liquid；
(2) said extracted liquid is reclaimed into ethanol in temperature≤45 DEG C concentrating under reduced pressure, obtains crude extract 530g；The extract is soaked
Cream is scattered in 6L water into suspension, and suspension is distinguished with petroleum ether (4L), ethyl acetate (4L) and n-butyl alcohol (2L) successively
Extraction three times, gained extract concentrating under reduced pressure respectively obtain Petroleum ether extraction extractum (58g), ethyl acetate and extract extractum (186g)
With n-butanol extraction extractum (152g)；
(3) ethyl acetate extract is carried out into silica gel column chromatography, with petroleum ether/acetone gradient elution；The concentration of gradient elution
It is followed successively by volume ratio 100:0、90:10、80:20、70:30、50:50、30:70 and 0:100, similar stream is merged according to TLC colour developings
Part obtains 4 components (A, B, C, D)；Component B is petroleum ether/acetone volume ratio 8:2 and 7:3 elution fraction Jing Sephadex LH-
20 gel filtration chromatographies, chromatographic column specification：4.0 (diameter) cm × 120 (length) cm；Sephadex LH-20 gel dry weights 150g,
With methylene chloride/methanol volume ratio 1:1 eluting, according to TLC colour developings merge similar stream part obtain 6 components (B1, B2, B3, B4,
B5、B6)；Component B3, i.e. methylene chloride/methanol volume ratio 1:1 elution volume is 90～120mL elution fractions, then Jing silicagel columns
Chromatography, with petroleum ether/acetone volume ratio 75:25 eluting, most after Jing preparation HPLCs (filler of chromatographic column be RP-18), with first
Alcohol/water volume ratio 80:20 eluting, flow velocity are 3.5mL/min, and retention time is 16.8min, obtain compound 3,5- dihydroxy-
2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl.
The test of 2 PTP1B inhibitory activity of embodiment：
Test philosophy：See Fig. 1.People source protein TYR phosphoric acid is expressed in E. coli system using molecular biology method
Esterase 1B (hPTP1B) catalyst structure domain, it is purified after hPTP1B recombiant proteins can hydrolyze substrate p-nitrophenyl phosphoric acid (p-
Nitrophenyl phosphate, pNPP) phospholipid key, obtain yellow soluble product paranitrophenol (p-
Nitrophenol), the product has very strong light absorbs at 410nm, therefore can be with the change of light absorbs at direct detection 410nm
Change and observe the suppression situation of the activity change and compound of enzyme to enzymatic activity.
The live body system of standard：10mM Tris.Cl tri- (methylol) aminomethane hydrochloride), pH 7.6,10mM
PNPP, 2%DMSO, 100nM hPTP1B.
Observation index：Dynamic measurement wavelength is the light absorbs at 410nm, and the time is 3 minutes, and its kinetic curve one-level is anti-
Activity index of the slope answered as enzyme.
Test method：Protein-tyrosine-phosphatase PTP1B for screening is from expression in escherichia coli and purification
Gst fusion protein.Using ultraviolet suitable substrates p-nitrophenyl phosphoric acid (pNPP), suppression of the variable concentrations to the activity of recombinase is observed
Make and use, with the medicinal effects of preliminary assessment compound.Sample is dissolved in into DMSO before use and is made into debita spissitudo, 3 times dilute, 7
Individual dilution factor, arranges three wells, takes 2 μ L samples solution and adds 96 orifice plates, is subsequently adding 88 μ L assay mix (assay
Buffer, pNPP, H2O), 10 μ L PTP1B are added.It is at 410nm that 96 orifice plates are placed in dynamic detection wavelength on VERSAmax
Detection absorbance value, time are 3 minutes.
The judge of experimental result and explanation：
The selection result is percent inhibition of the compound concentration to enzymatic activity when being 20 μ g/ml, when suppression ratio is higher than 50%,
Routinely (the detected diluted chemical compound by suppression ratio higher than 50% is carried out into different concentration according to above-mentioned method of testing for screening
Reaction, all tests are respectively provided with multiple holes) draw IC50, the IC of positive control oleanolic acid50For 2.74 ± 0.20 μM.
Experimental result：Compound 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl pair
The IC of PTP1B enzyme inhibition activities50For 2.23 ± 0.14 μM.
Experiment conclusion：By molecular biology test, it can be seen that compound 3,5- dihydroxy -2- [3,7- dimethyl -2
(trans), 6- octadienyls]-bibenzyl to protein tyrosine esterase 1B (PTP1B) with preferable inhibitory activity, so as to can be used for
Prepare the medicine for the treatment of diabetes, obesity and its complication.
Claims (2)
1.3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl can as the active component of medicine,
Can be made into tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation, nanometer formulation or injection to suppress as PTP1B
Agent, for treating diabetes, obesity and its complication.
2.3,5- dihydroxy -2- [3,7- dimethyl -2 (trans), 6- octadienyls]-bibenzyl can as the activity of health product into
Point, can be made into tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation or nanometer formulation for diabeticss or
The health food of obese patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611092879.2A CN106580933B (en) | 2016-12-01 | 2016-12-01 | The purposes of 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans-), 6- octadienyl]-bibenzyl |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611092879.2A CN106580933B (en) | 2016-12-01 | 2016-12-01 | The purposes of 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans-), 6- octadienyl]-bibenzyl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106580933A true CN106580933A (en) | 2017-04-26 |
| CN106580933B CN106580933B (en) | 2019-04-12 |
Family
ID=58594884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611092879.2A Active CN106580933B (en) | 2016-12-01 | 2016-12-01 | The purposes of 3,5- dihydroxy -2- [3,7- dimethyl -2 (trans-), 6- octadienyl]-bibenzyl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106580933B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058701A1 (en) * | 2000-08-16 | 2002-05-16 | Inman Wayne D. | Compositions containing hypoglycemically active stilbenoids |
-
2016
- 2016-12-01 CN CN201611092879.2A patent/CN106580933B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058701A1 (en) * | 2000-08-16 | 2002-05-16 | Inman Wayne D. | Compositions containing hypoglycemically active stilbenoids |
Non-Patent Citations (3)
| Title |
|---|
| KAZUHIKO OTOGURO等: "In vitro antitrypanosomal activity of bis(bibenzyls)s and bibenzyls from liverworts against Trypanosoma brucei.", 《J NAT MED》 * |
| LIVA HARINANTENAINA等: "Chemical Constituents of Malagasy Liverworts, Part V: Prenyl Bibenzyls and Clerodane Diterpenoids with Nitric Oxide Inhibitory Activity from Radula appressa and Thysananthus spathulistipus.", 《CHEM. PHARM. BULL.》 * |
| YOSHINORI ASAKAWA等: "Prenyl bibenzyls from the liverwort Radula kojana", 《PHYTOCHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106580933B (en) | 2019-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Anti-diabetic effect of methylswertianin and bellidifolin from Swertia punicea Hemsl. and its potential mechanism | |
| CN106748666B (en) | Natural medicine for reducing blood sugar and its use in preparing medicine for diabetes or obesity | |
| CN106916133B (en) | One kind, which has, inhibits active phloroglucin derivative of PTP1B and preparation method thereof, application | |
| CN103222988A (en) | Periplaneta americana extract and its preparation method and use | |
| CN107802626B (en) | Hypoglycemic composition and preparation method and application thereof | |
| CN107805269A (en) | DICTYOPTERISINF and its prepare application in diabetes or obesity drug | |
| CN112645808A (en) | 5-hydroxy-1, 7-diphenyl-3-heptanone separated from galangal and application thereof | |
| CN105136966B (en) | A kind of quality determining method of Liang Fu Wan class preparation | |
| CN107674108B (en) | Application of stigmastane steroid compound in preparing medicine for treating diabetes or obesity | |
| CN101829224A (en) | Traditional Chinese medicine composition preparation and preparation method and quality control method | |
| CN102068549B (en) | Detection method for Chinese medicinal preparation heat clearing and blood cooling pills | |
| CN102068656B (en) | Quality control method for traditional Chinese medicinal preparation epilepsy pills | |
| CN104688933B (en) | Composition of Pu' er tea effective components and application thereof in preparing hypoglycemic drug or health food | |
| CN112552155A (en) | 1, 7-diphenyl-4-heptylene-3-ketone separated from galangal and application thereof | |
| Kurniasari et al. | Phytochemical analysis and anticancer activity of seaweed Gracilaria verrucosa against colorectal HCT-116 cells | |
| CN101474314A (en) | Application of catechin in pharmacy | |
| CN104224813A (en) | Pharmaceutical composition as well as preparation method and application thereof | |
| CN105949104B (en) | A kind of purposes of the chain diterpene-kind compound of haematinic acid esterification | |
| CN107652347B (en) | Compound Dictyopterissini I and application thereof in preparation of diabetes or obesity medicines | |
| CN106580933A (en) | Application of 3,5-dihydroxy-2-[3,7-dimethyl-2(E),6-octadienyl]-bibenzyl | |
| CN101439083B (en) | Detection method of Chinese medicine soft capsules for clearing wind heat and clearing nasal passage | |
| CN106748664B (en) | Novel bibenzyl natural medicine with blood sugar reducing effect and application thereof | |
| CN103055191B (en) | Preparation method and quality detection method of traditional Chinese medicine for treating hematuresis caused by nephritis | |
| CN106748778B (en) | New bibenzyl natural medicine with hypoglycemic effect and its prepn and use | |
| CN108774276A (en) | Radix Viburni fordiae fruit lignans extract and its active constituent and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201217 Address after: 221300 Yaoxi neighborhood committee, bayiji Town, Pizhou City, Xuzhou City, Jiangsu Province Patentee after: Xuzhou kangshiju Construction Technology Co., Ltd Address before: 999 No. 330031 Jiangxi province Nanchang Honggutan University Avenue Patentee before: Nanchang University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211228 Address after: 721000 Fufeng jiangzhang Industrial Park, jiangzhang Town, Fufeng County, Baoji City, Shaanxi Province Patentee after: Shaanxi Xiyue Pharmaceutical (Fufeng) Co.,Ltd. Address before: 221300 Yaoxi neighborhood committee, bayiji Town, Pizhou City, Xuzhou City, Jiangsu Province Patentee before: Xuzhou kangshiju Construction Technology Co., Ltd |